167 results about "Encephalopathy" patented technology

A chimeric autoantibody receptor (CAAR) that enables targeting of an immune cell to autoantibody producing B cells. The CAAR includes an autoantigen or fragment thereof that is bound by autoantibodies associated with neurological autoimmune disease primarily targeting the central nervous system. Also disclosed is a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid sequence encoding an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system, a transmembrane domain, and an intracellular signaling domain, a vector comprising a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), a genetically modified immune cell comprising the nucleic acid molecule encoding the CAAR and use of the immune cell in the treatment or prevention of a neurological autoimmune disease primarily targeting the central nervous system, such as an autoimmune encephalopathy or encephalomyelopathy, preferably anti-NMDAR encephalitis.

Aspects of the invention provide an AAV product that delivers an STXBP1 gene supplementation or replacement strategy throughout the human CNS at levels of DNA biodistribution, RNA expression, and hSTXBPlb protein levels expected to restore function in STXBP1 encephalopathy patients.

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

The disclosure concerns compositions and methods for treatment of encephalopathies, including encephalopathies caused by, or associated with, and STXBP1 haploinsufficiency or mutation. Compositions and methods provided herein encompass AAV particles that encapsidate the STXBP1 transgene and allow for STXBP1 expression, including expression of STXBP1 in central and / or peripheral nervous system cells.

Aspects of the disclosure relate to oligosaccharide compositions and methods of making the same. Also provided are methods of using oligosaccharide compositions as microbiome metabolic therapies for reducing ammonia levels and for the treatment of hyperammonemia-related diseases (e.g., urea cycle disorders and hepatic encephalopathy).

The invention relates to the field of biomedical application of inorganic materials, in particular to application of lanthanum carbonate in preparation of a medicine for treating hepatic encephalopathy. According to the application of lanthanum carbonate in preparation of the medicine for treating hepatic encephalopathy, the medicine comprises lanthanum carbonate and pharmaceutically acceptable auxiliary materials, the lanthanum carbonate comprises any one or more of lanthanum carbonate hydrate and basic lanthanum carbonate, the medicine is ground and then mixed with food to prepare a medicine mixture, and the medicine mixture is prepared into the medicine for treating hepatic encephalopathy. The mass ratio of the lanthanum carbonate in the medicine mixture is 1-10%. According to the application, the blood ammonia is reduced based on the glutaminase, the hepatic encephalopathy is reversed by reducing the blood ammonia and systemic inflammation, and the liver function is recovered by regulating the inflammation, so that the hepatic encephalopathy is favorably cured, a good treatment effect is shown, and a new candidate medicine is provided for clinically treating the hepatic encephalopathy.

The invention relates to anti-TDP-43 binding molecules and uses thereof. The present invention is in the field of trans-activation responsive DNA binding proteins (TARDB or also referred to as TDP-43) having a molecular weight of 43 kDa. The present invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or antigen binding fragments or derivatives thereof, and uses thereof. The present invention provides means and methods for diagnosing, preventing, ameliorating and / or treating diseases, disorders and / or abnormalities associated with TDP-43 aggregates, including, but not limited to, frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), chronic traumatic encephalopathy (CTE), and edge-dominant age-related TDP-43 encephalopathy (LATE).

The invention pertains to a new computer-implemented method for processing an EEG signal, that makes it possible to extract information about cerebral damage in full-term babies, born in asphyxia context, for help in an indication for treatment of hypoxic-ischemic encephalopathy (HIE), by computing a power spectral density (PSD) of an EEG signal, transforming the PSD by a mathematical function, processing the transformed values by data binning, and creating a probability distribution of the durations of the binned values.

The invention discloses a pharmaceutical composition for treating KCNQ2 developmental epileptic encephalopathy, a nucleic acid construct and application of the pharmaceutical composition and the nucleic acid construct. According to the invention, by introducing a nucleic acid construct carrying the hKCNQ2 gene into a KCNQ2A294V / + developmental epileptic encephalopathy animal model and a human forebrain neuron model, the effectiveness of the nucleic acid construct in improving the expression level of the KCNQ2 and improving related neuropathological mechanisms is verified. Not only is a new hope provided for treatment of KCNQ2-related developmental epileptic encephalopathy provided, but also a new direction is opened up for application of gene therapy in neurodevelopmental diseases.

The present disclosure provides freeze-dried and liquid compositions that include an extract of human feces. Also provided are methods for making and using such compositions, including methods for replacing or supplementing or modifying a subject's intestinal microbiota, and methods for treating a disease or condition such as hepatic encephalopathy.

This invention discloses a polyethylene glycol-modified magnesium boride nanosheet and its application in treating acute liver failure and hepatic encephalopathy caused by acetaminophen. The nanosheet uses magnesium boride nanosheets as a core, with polyethylene glycol modified on the surface to improve biocompatibility. The nanosheet of this invention exhibits good antioxidant properties and can be used to prepare nanomedicines for treating acute liver failure and / or hepatic encephalopathy caused by acetaminophen. It generates reducing hydrogen gas through a hydrolysis reaction, effectively scavenging reactive oxygen species at the site of liver failure, thereby inhibiting inflammatory responses and effectively alleviating symptoms caused by acute liver failure.

The utility model is suitable for the technical field of rehabilitation training gloves, and provides an auxiliary glove for rehabilitation training of encephalopathy. The male magic tape is sewn on the outer wall of one side of the wrist strap through a needle and a thread; the female magic tape is sewn on the outer wall of the other side of the wrist strap through a needle and a thread; the corrugated telescopic band is fixed at the top of the wrist band; the connecting belt is fixed at the top of the corrugated telescopic belt; the palm sleeve is fixed at the top of the connecting band; the fingerstalls and the palm center belt are integrally formed on the inner side wall of the palm sleeve, and the fingerstalls are located above the palm center belt; expansion and contraction of the first air bag and the second air bag are achieved by controlling inlet and outlet of air in the first air bag and the second air bag, angle adjustment of the wrist strap and the palm sleeve is achieved through pushing force and pulling force generated by deformation of the first air bag and the second air bag, and therefore wrist movement is controlled, and rehabilitation training of hand wrist joints is facilitated. Manual auxiliary training is not needed, and manpower is greatly saved.

To provide stabilization of a retromer for treating Alzheimer disease and other neurodegenerative disorders.SOLUTION: Provided is a method and a composition for increasing and stabilizing a retromer in order to treat and / or prevent Alzheimer disease and other neurodegenerative disorders. Furthermore, provided is treatment of an adenovirus base for treating Alzheimer disease (AD), and other neurodegenerative states, which are Parkinson disease (PD), neuronal ceroid lipofuscinosis (NCL), and transmissible spongiform encephalopathy (TSE or prion disease), multiple system atrophy (MSA), Down syndrome, and hereditary spastic paraplegia for example, and which are progressive supranuclear palsy (PSP), frontotemporal dementia linked to chromosomes 17q21 to 22 and subtype (FTLD-17 / FTLD-Tau) thereof, Lewy body disease (LBD), amyotrophic lateral sclerosis (AES), frontotemporal degeneration (FTD), ALS-FTD and chronic traumatic encephalopathy (CTE) for example.SELECTED DRAWING: None

The application discloses application of a Fructus Mume pill in preparation of a medicine for treating diabetic encephalopathy, and finds that there is a clear correlation between the Fructus Mume pill and the diabetic encephalopathy. Research results show that the Fructus Mume pill can improve the abnormal metabolic state of a diabetic model mouse, reduce learning and memory dysfunction and cognitive impairment under a diabetic state, and has a good prevention and treatment effect on the diabetic encephalopathy. The application clearly defines the pharmacological effect of the Fructus Mume pill in preventing and treating the diabetic encephalopathy and a possible action mechanism, and provides an experimental basis for TCM intervention on the diabetic encephalopathy. The application provides a new train of thought for research and development of a medicine related to the diabetic encephalopathy, and has a good application prospect.

The invention belongs to the technical field of medicines, and particularly relates to application of penicillin tenuipes in preparation of a product for preventing or treating ischemic encephalopathy, cell experiments and animal experiments show that penicillin tenuipes has a good treatment effect on cerebral thrombosis and middle artery embolism, can obviously improve behavioral scores after ischemia, and can be used for preparing a medicine for preventing or treating ischemic encephalopathy. And cerebral thrombus and blood vessel diameter conditions. The penicillin tenuipes also has an anti-inflammatory effect. Therefore, the compound can be used for preparing medicines for preventing or treating ischemic encephalopathy.

The application discloses a kind of based on brain structure image's hepatic encephalopathy evaluation method and system, the method includes: obtaining the brain structure image data of subject brain;Based on brain structure image data, the feature parameter of characterizing brain tissue morphology is extracted;The characteristic parameter is handled by pre-training disease progression evaluation model, and the space-time progression trajectory of brain structure abnormality is inferred;Based on space-time progression trajectory, the disease subtype and disease progression stage to which the subject belongs are determined;Based on disease subtype and disease progression stage, evaluation information for characterizing the disease state of hepatic encephalopathy is generated.The space-time progression trajectory of brain structure abnormality is inferred based on cross-sectional image data, which overcomes the dependence on massive longitudinal tracking data, realizes the objective typing and staging of hepatic encephalopathy based on neurobiology, thereby effectively solving the technical problems of difficult to track disease evolution and individualized evaluation.

A TIPS (Transient Invasive Stent) for flow restriction includes a bare stent with a fixed stent connected to one side. A flow-restricting stent is disposed inside the fixed stent. The flow-restricting stent has a conical structure, with the larger end of the conical stent connected to the inner side of the fixed stent, and the smaller end of the conical stent facing the other end of the fixed stent. A drug-eluting layer is disposed inside the fixed stent. In this application, the flow-restricting stent is a streamlined cone shape with a diameter that gradually decreases from one end to the other. This conical design reduces blood flow turbulence and recirculation, lowers the risk of thrombosis, maintains high stent patency, and more rationally balances the relationship between portal hypertension and hepatic encephalopathy, thus improving patients' quality of life. In some patients, it can more stably maintain the postoperative portal vein pressure gradient within the safe range of 10-12 mmHg. The conical structure achieves a smooth pressure gradient change through a gradually decreasing diameter, which is more in line with the principles of fluid dynamics and has high clinical value in preventing hepatic encephalopathy.

The invention provides an image-clinical characterization-combined multi-endpoint prognosis evaluation method for transjugular vein intrahepatic portal vein shunt, which comprises the following steps of: constructing a few-label portal vein segmentation module to obtain a preoperative CT portal vein label of a full-dose patient, and extracting deep learning features and radiomics features of the region; establishing a multi-modal interactive representation learning module for implementation, and performing cross-modal fusion with clinical features to form unified representation; and designing a multi-endpoint prognosis prediction module, inputting the data to a plurality of prognosis task decoders for postoperative survival, portal vein pressure gradient, hepatic encephalopathy prediction and the like, and adopting a multi-task learning optimization model to obtain a postoperative multi-endpoint prognosis evaluation result. According to the method, efficient fusion and multi-endpoint prognosis prediction of images and clinical information can be realized under limited labeling, clinical doctors can be assisted in preoperative patient screening and treatment scheme making, and the method has good clinical application value.

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein Ring A, Ring B, R1, R2, R3, R12, and L are as defined herein. The compounds are antagonists of the resistant (R-type) voltage-gated calcium ion channel Cav 2.3. Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases modulated Cav 2.3, including epilepsy, neurodegenerative conditions such as Parkinson's disease, focal, drug-resistant forms of epilepsy, and other neurological disorders such as developmental and epileptic encephalopathies and Phelan-McDermid and Fragile X syndromes.

Provided are methods of using glycosaminoglycans (GAGs) levels in a biological sample as a means to diagnose, assess prognosis, and ascertain whether treatment is efficacious in a wide variety of diseases other than mucopolysaccharidoses (MPS). In certain embodiments, the methods relate to clinical diagnosis of viral or non-viral encephalopathy.

The present application relates to the technical field of medical apparatus and instruments, and discloses a neonatal hypothermia portable treatment device and a body temperature regulation system, aiming to solve the problem that the prior art cannot adapt to the transfer scene and is prone to body temperature out of control when a neonatal hypoxic-ischemic encephalopathy is transferred, the body temperature regulation system comprises four modules of information acquisition, temperature control decision, temperature control execution and information connection, the information acquisition module collects and discriminates body temperature, physiological parameters and transfer interference data; the temperature control decision module generates temperature control instructions and interference compensation strategies in combination with preset parameters of body weight and according to scenes; the temperature control execution module drives components to land on the ground according to instructions and feeds back the state; and the information connection module summarizes data and synchronously transfers the data into a hospital admission system, so that the transition body temperature is stably controlled during the transfer, the hospital admission first-aid operation is smoothly connected, and the technical blank of pre-treatment body temperature transition management during short-distance transfer is filled.

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of KCNT1 RNA in a cell or subject, and in certain instances reducing the amount of KCNT1 protein in a cell or subject. These compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurological condition. Such symptoms and hallmarks include seizures, encephalopathy, and behavioral abnormalities. Non-limiting examples of neurological conditions that benefit from these compounds, methods, and pharmaceutical compositions are epilepsy of infancy with migrating focal seizures (EIMFS), autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), West syndrome, and Ohtahara syndrome.

The disclosure relates to polynucleotides, e.g., viral genomes, encoding syntaxin-binding protein-1 (STXBP1), vectors, e.g., adeno-associated virus (AAV) particles, comprising said polynucleotides, compositions comprising said polynucleotides or vectors, and methods of making or delivering to a cell or subject. The polynucleotides, vectors, compositions, and methods of the present disclosure are useful for the treatment of subjects who have, have been diagnosed with having, or are at risk of having a STXBP1-related disorder, e.g., STXBP1 Developmental and Epileptic Encephalopathy (DEE) and / or other STXBP1-related disorders, or at least one symptom thereof.

The application relates to the biomedical application field of inorganic materials, and particularly relates to application of lanthanum carbonate in preparation of a medicine for treating hepatic encephalopathy. The application relates to application of lanthanum carbonate in preparation of a medicine for treating hepatic encephalopathy, wherein the medicine comprises lanthanum carbonate and pharmaceutically acceptable adjuvants, and the lanthanum carbonate comprises any one or more of lanthanum carbonate hydrate and basic lanthanum carbonate. The application is based on the fact that glutamine enzyme can reduce blood ammonia, and the hepatic encephalopathy is reversed by reducing blood ammonia and systemic inflammation, the liver function is recovered by regulating inflammation, thereby helping to cure the hepatic encephalopathy, and good treatment effect is shown, so that a new candidate medicine for clinically treating the hepatic encephalopathy is provided.

The application discloses a cerebrospinal fluid auxiliary diagnosis marker for neuropsychiatric lupus, and relates to the application of any one or more of TCN2, CST6, Trappin-2 and L-selectin as a diagnosis marker in the preparation of a cerebrospinal fluid auxiliary diagnosis reagent for neuropsychiatric lupus. The application provides four biomarkers of TCN2, etc. with high specificity and high sensitivity for diagnosing neuropsychiatric lupus, fills the blank in the field, further improves the accuracy of diagnosis, helps to realize timely early warning in clinic, and helps to establish a new clinical diagnosis standard for lupus encephalopathy.

The present invention relates to a method of preventing and / or treating chronic traumatic encephalopathy.

The invention discloses a method, equipment, medium and program product for evaluating the treatment effect of levosimendan on sepsis-related encephalopathy. According to the method, the treatment effect of the levosimendan on the sepsis-related encephalopathy is evaluated on the basis of cerebral blood flow data, clearance rate data of a colloidal lymphatic system and / or expression data of AQP4, and the treatment effect of the levosimendan on the sepsis-related encephalopathy can be effectively evaluated. Therefore, further guidance is provided for optimizing the treatment condition and research of the sepsis-related encephalopathy by the levosimendan, and a clinician can be guided to formulate an individualized treatment scheme for a patient.

The present invention relates to compounds which are suitable for imaging TDP-43 (Transactive response (TAR) DNA binding protein 43 kDa) aggregates. The compounds can be used, for example, for diagnosing a disease, disorder or abnormality associated with TDP-43 aggregates or a TDP-43 proteinopathy, such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Frontotemporal dementia (FTD) and limbic-predominant age-related TDP-43 encephalopathy (LATE).

The invention relates to application of sevelamer. The medicine is particularly applied to treatment of hepatic encephalopathy. According to the method for orally taking the sevelamer compound preparation, the level of ammonia in blood can be remarkably reduced to the normal level, bile acid in the intestinal tract is combined, system inflammation is reduced, and therefore the sevelamer compound preparation is beneficial to curing hepatic encephalopathy, and no obvious side effect is found; the sevelamer oral administration method provided by the invention has a remarkable treatment effect on hepatic encephalopathy, a new candidate treatment medicine is expected to be brought to clinical hepatic encephalopathy, and meanwhile, the range of indications of sevelamer in clinical treatment is widened.